Clinical trial · Observational
Intraoperative Continuous Terlipressin Infusion is Associated With Reduced Severe Postoperative Complications After Laparoscopic Hepatectomy: a Prospective Propensity Score-matched Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Liver resection is an important surgical treatment for patients with liver diseases. Despite advances in surgical and anesthetic management, postoperative complications remain a major concern and may affect patient recovery. Maintaining stable blood circulation during surgery is an important part of perioperative care. Terlipressin is a vasoactive medication that may help maintain blood pressure and improve hemodynamic stability during surgery. However, the relationship between intraoperative continuous terlipressin infusion and postoperative outcomes after laparoscopic hepatectomy remains unclear. This prospective observational cohort study aims to evaluate the association between continuous intraoperative terlipressin infusion and postoperative severe complications in patients undergoing laparoscopic hepatectomy. Patients undergoing laparoscopic hepatectomy at the First Affiliated Hospital of Sun Yat-sen University will be enrolled and followed according to a predefined study protocol. Perioperative clinical information, anesthetic management data, terlipressin exposure, and postoperative outcomes will be collected and analyzed. The primary outcome is the occurrence of severe postoperative complications, defined as Clavien-Dindo grade III or higher complications.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Neoplasms | Liver Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Postoperative Complications | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| terlipressin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Terlipressin Exposure Group
- description
- Patients who received continuous intraoperative terlipressin infusion during laparoscopic hepatectomy according to the clinical judgment of the attending anesthesiologist. Terlipressin administration was not assigned by the study protocol and was determined based on routine clinical practice.
- interventionNames
- Drug: terlipressin
- label
- Non-Terlipressin Exposure Group
- description
- Patients who underwent laparoscopic hepatectomy and did not receive continuous intraoperative terlipressin infusion during surgery. The absence of terlipressin administration was determined by routine clinical practice.
Primary outcomes (1)
- measure
- Incidence of severe postoperative complications
- timeFrame
- Within 30 days after surgery
- description
- Severe postoperative complications will be defined as Clavien-Dindo grade III or higher complications occurring after laparoscopic hepatectomy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Adults aged 18 to 80 years * American Society of Anesthesiologists (ASA) physical status I-III * Scheduled for elective laparoscopic partial hepatectomy * Provided written informed consent Exclusion Criteria: * Inability to tolerate the planned surgical procedure based on pre-anesthetic assessment * Severe hepatic dysfunction (Child-Pugh class B or higher) * Severe renal dysfunction (blood urea nitrogen \> 9 mmol/L or serum creatinine \> 178 μmol/L) * Significant cardiovascular or cerebrovascular disease, including active coronary artery disease, severe valvular stenosis, hypertrophic obstructive cardiomyopathy, or history of extensive cerebral infarction * Known allergy to study medications * Body mass index (BMI) \> 35 kg/m² or \< 18 kg/m² * Hemoglobin level \< 90 g/L * Pregnancy or lactation * Participation in another clinical trial within the preceding 3 months * Any other condition considered inappropriate for study participation by the investigator
References
Publications (0)
Data not yet available